alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid has been researched along with ethosuximide in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (50.00) | 18.2507 |
| 2000's | 1 (50.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barrionuevo, G; Henze, DA; Urban, NN | 1 |
| Chimirri, A; Citraro, R; De Fazio, S; De Sarro, G; Di Paola, ED; Gitto, R; Marra, R; Russo, E | 1 |
2 other study(ies) available for alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid and ethosuximide
| Article | Year |
|---|---|
Amplification of perforant-path EPSPs in CA3 pyramidal cells by LVA calcium and sodium channels.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Calcium Channel Blockers; Calcium Channels; Electric Stimulation; Ethosuximide; Excitatory Amino Acid Agonists; Excitatory Postsynaptic Potentials; Hippocampus; Ion Channel Gating; Male; Neural Pathways; Nickel; Nifedipine; Perforant Pathway; Pyramidal Cells; Rats; Rats, Sprague-Dawley; Sodium Channels; Tetrodotoxin | 1998 |
Enhancement of anti-absence effects of ethosuximide by low doses of a noncompetitive alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor antagonist in a genetic animal model of absence epilepsy.
Topics: alpha-Amino-3-hydroxy-5-methyl-4-isoxazolepropionic Acid; Animals; Anticonvulsants; Cerebral Cortex; Disease Models, Animal; Dose-Response Relationship, Drug; Drug Synergism; Electroencephalography; Epilepsy, Absence; Ethosuximide; Injections, Intraperitoneal; Injections, Intraventricular; Male; Mice; Mice, Inbred Strains; Receptors, AMPA; Tetrahydroisoquinolines | 2008 |